NFL Concludes Eagles Handled Jalen Hurts Blood Clot Situation Appropriately

The National Football League has concluded its review into the Philadelphia Eagles' handling of quarterback Jalen Hurts' blood clot situation and found no wrongdoing by the team, a league source confirmed Tuesday. The matter is now considered closed by the NFL.

The review stemmed from the designation of Hurts for the Eagles' Week 5 game against the Jacksonville Jaguars in London. The Eagles did not initially disclose that Hurts had been found to have a superficial blood clot the day before the game, a detail that emerged later. Hurts played in the game and participated in practices in the subsequent days.

However, further evaluations later in the week revealed Hurts had a deep vein thrombosis and bilateral pulmonary emboli. The team and Hurts' agent announced these findings on Monday, and Hurts is sidelined for the remainder of the season.

The Eagles stated they were in contact with the NFL throughout the process. This included the league's chief medical officer arranging for Hurts to be seen at the Cleveland Clinic in London on the Saturday before the Jaguars game. The NFL released a statement indicating its chief medical officer, Dr. Allen Sills, coordinates medical resources with leading providers in international markets, and that player medical care is a collaboration between club medical staff and independent doctors.

Following the initial discovery of the superficial blood clot in Hurts' calf, the team, medical staff, and Hurts himself determined he was able to play. Head coach Nick Sirianni addressed the situation briefly, emphasizing the team's focus on player well-being and their trust in medical experts. General Manager Howie Roseman, who oversees the medical staff, did not comment on the matter, adhering to his usual practice of deferring to the coaching staff during the season.

Despite the NFL's clearance, the initial lack of transparency from the team has led to ongoing questions about the situation.